- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02834130
Input of a Multidisciplinary Device to Accompany the Announce of Diagnosis for Young Children With Serious Constitutional Hemorrhagic Disease and Their Families (ACADHEM)
Input of a Multidisciplinary Device Including a Psychological Approach, to Accompany the Announce of Diagnosis for Young Children With Serious Constitutional Hemorrhagic Disease and Their Families
Severe forms of hemophilia and other constitutional bleeding disorders represent a group of rare diseases. In last decades, news therapies have dramatically increased life expectancy and joint's protection.
The investigators propose to set up a single-centre, descriptive, transversal pilot study, designed for the inclusion of around thirty children from 2 to 10 years, with haemophilia or allied hereditary bleeding disorders (HBD), who were referred to the Hemophilia Treatment Center (HTC) of Marseille at diagnosis. For those children who were able to benefit from the totality or part of the device accompanying the diagnostic announcement in the past 10 years.
Study Overview
Status
Intervention / Treatment
Detailed Description
Severe forms of hemophilia and other constitutional bleeding disorders represent a group of rare diseases. In last decades, news therapies have dramatically increased life expectancy and joint's protection. The recurrence of joint bleedings is responsive of multifocal arthropathy in the natural history, but nowadays, the orthopedic outcome is good thanks to prophylactic treatments.
However, the announcement of the diagnosis of such hereditary bleeding disorders at a very young age represents a real psychological trauma for parents. Such an announcement may induce some psycho-developmental impairment.
An innovative support has been implemented at the Hemophilia Treatment Center in Marseille, in conjunction with the French Hemophilia Society. This program is based on a multidisciplinary partnership that favors the psychological support and the reinsurance of the parents.
With Rare Diseases Foundation support, the investigators have initiated this pilot study that will include more than 20 patients with severe hemophilia or constitutional bleeding disorder, who benefit from the device. This descriptive, monocentric, interventional study will permit to describe the psychological status, the quality of life of patients and their parents, but also to evaluate the impact of the device on initiation and observance of treatments like Long Term Prophylaxis.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Marseille, France, 13354
- Hopital Enfants de la Timone Assistance Publique Hôpitaux de Marseille
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged between 3 and 12 years
- Patients diagnosed and treated at the Center until inclusion
- Patients with FVIII :C < 2% or with FIX :C <2% or with FVII:C <2% or with FXIII:C <2% or fibrinogen <0,2 g/l, or with type 3 von Willebrand diseases or Thrombasthenia of Glanzmann diseases.
- Patient who participate to multidisciplinary support and announcement of diagnosis device
- Voluntarily given fully informed written and signed consents obtained before any study-related procedures are conducted
Exclusion Criteria:
- Patient with other clotting disorder or disease.
- Patient diagnosed or treated in other centre
- Patient with psychiatric disorder or disease
- Patient with other severe chronic disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: children from 2 to 10 years with haemophilia or allied HBD, wh
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Treatment Exposure Days compared to the Number of Treatment Exposure days prescribed
Time Frame: 2 years
|
Treatment Observance
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Assessment of patient's behavioral condition using the Child Behavior Check-list (CBCL) 1,5-5
Time Frame: 2 Years
|
2 Years
|
|
Assessment of the patient's body consciousness through the "CORP-R" test (french test of body mapping)
Time Frame: 2 years
|
2 years
|
|
Assessment of patient's quality of life using the "Kidscreen" questionnaire for children
Time Frame: 2 years
|
2 years
|
|
Assessment of the patient's parents' Qaulity of life through the Short Form Health Survey (SF-36)
Time Frame: 2 Years
|
2 Years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-05
- 2014-A00367-40 (Registry Identifier: Ansm)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Forms of Hemophilia
-
University of Mary Hardin-BaylorPharmachem InnovationsCompletedEvaluation of Bioavailability of Supplemental Forms of IronUnited States
-
Changhai HospitalUnknown
-
BiogenNot yet recruiting
-
University of KansasFutures Without ViolenceUnknownDomestic Violence | Multiple Forms of Child AbuseUnited States
-
Christoph KönigsRoche Pharma AG; Chugai Pharma Germany GmbHRecruitingSevere Hemophilia A | Severe Hemophilia A With Inhibitor | Severe Hemophilia A Without InhibitorGermany
-
Charite University, Berlin, GermanyRecruitingVarious Forms of Skeletal Muscle DystrophyGermany
-
University College, LondonRecruiting
-
Assistance Publique - Hôpitaux de ParisCompletedIvermectin | Gale | Severe Forms of Scabies | Oral Parasitic DrugFrance
-
BiogenTerminatedRelapsing Forms of MSIsrael
-
University Hospital, RouenRecruitingSevere Forms of Mucous Membrane PemphigoidFrance
Clinical Trials on Evaluation of psychological and psychopathological
-
Centre Hospitalier Universitaire de NiceCompletedEnd Stage Renal FailureFrance
-
University Hospital, AngersTerminated
-
University Hospital, CataniaUnknownDepression | Anxiety | Hereditary AngioEdemaItaly
-
University Hospital, BordeauxRecruitingMultiple SclerosisFrance
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingUterine Cervical NeoplasmsItaly
-
Parc de Salut MarUniversitat Autonoma de BarcelonaCompletedPsychotic Disorders | Stress, Psychological | Psychological Trauma | Cross-Cultural ComparisonSpain
-
University Hospital, BordeauxRoche Pharma AGActive, not recruitingMultiple Sclerosis, Primary ProgressiveFrance
-
Fondation LenvalCompleted
-
Centre Hospitalier de Moulins YzeureRecruitingBody Weight ChangesFrance
-
Matteo TonnaSan Raffaele University Hospital, ItalyActive, not recruitingSchizophrenia and Schizophrenia Spectrum Psychosis | Obsessive-Compulsive Disorder (OCD)Italy